Vistagen Therapeutics Stock Probability of Future Stock Price Finishing Over 4.70

VTGN Stock  USD 4.70  0.03  0.64%   
VistaGen Therapeutics' implied volatility is one of the determining factors in the pricing options written on VistaGen Therapeutics. Implied volatility approximates the future value of VistaGen Therapeutics based on the option's current value. Options with high implied volatility have higher premiums and can be used to hedge the downside of investing in VistaGen Therapeutics over a specific time period. For example, 2024-04-19 CALL at $5.0 is a CALL option contract on VistaGen Therapeutics' common stock with a strick price of 5.0 expiring on 2024-04-19. The contract was last traded on 2024-04-17 at 14:31:34 for $0.1 and, as of today, has 1 days remaining before the expiration. The option is currently trading at a bid price of $0.05, and an ask price of $0.9. The implied volatility as of the 18th of April 2024 is 225.84. View All VistaGen options

Closest to current price VistaGen long CALL Option Payoff at Expiration

VistaGen Therapeutics' future price is the expected price of VistaGen Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of VistaGen Therapeutics performance during a given time horizon utilizing its historical volatility. Check out VistaGen Therapeutics Backtesting, VistaGen Therapeutics Valuation, VistaGen Therapeutics Correlation, VistaGen Therapeutics Hype Analysis, VistaGen Therapeutics Volatility, VistaGen Therapeutics History as well as VistaGen Therapeutics Performance.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
  
As of the 18th of April 2024, Price To Sales Ratio is likely to grow to -120.41. In addition to that, Price Earnings Ratio is likely to drop to -3,352. Please specify VistaGen Therapeutics' target price for which you would like VistaGen Therapeutics odds to be computed.

VistaGen Therapeutics Target Price Odds to finish over 4.70

The tendency of VistaGen Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 4.70 90 days 4.70 
about 60.58
Based on a normal probability distribution, the odds of VistaGen Therapeutics to move above the current price in 90 days from now is about 60.58 (This VistaGen Therapeutics probability density function shows the probability of VistaGen Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.95 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, VistaGen Therapeutics will likely underperform. Additionally VistaGen Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
   VistaGen Therapeutics Price Density   
       Price  

Predictive Modules for VistaGen Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as VistaGen Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of VistaGen Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.394.658.91
Details
Intrinsic
Valuation
LowRealHigh
2.056.3110.57
Details
4 Analysts
Consensus
LowTargetHigh
10.9212.0013.32
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.43-0.36-0.36
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as VistaGen Therapeutics. Your research has to be compared to or analyzed against VistaGen Therapeutics' peers to derive any actionable benefits. When done correctly, VistaGen Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in VistaGen Therapeutics.

VistaGen Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. VistaGen Therapeutics is not an exception. The market had few large corrections towards the VistaGen Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold VistaGen Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of VistaGen Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over NYSE Composite
-0.29
β
Beta against NYSE Composite2.95
σ
Overall volatility
0.41
Ir
Information ratio -0.05

VistaGen Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of VistaGen Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for VistaGen Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
VistaGen Therapeutics had very high historical volatility over the last 90 days
VistaGen Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (59.25 M) with loss before overhead, payroll, taxes, and interest of (227.3 K).
VistaGen Therapeutics currently holds about 51.99 M in cash with (49.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Roughly 63.0% of the company outstanding shares are owned by institutional investors
Latest headline from businesswire.com: Vistagen to Present at the 2024 Anxiety and Depression Association Conference

VistaGen Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of VistaGen Stock often depends not only on the future outlook of the current and potential VistaGen Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. VistaGen Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares OutstandingM
Cash And Short Term Investments16.6 M

VistaGen Therapeutics Technical Analysis

VistaGen Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. VistaGen Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of VistaGen Therapeutics. In general, you should focus on analyzing VistaGen Stock price patterns and their correlations with different microeconomic environments and drivers.

VistaGen Therapeutics Predictive Forecast Models

VistaGen Therapeutics' time-series forecasting models is one of many VistaGen Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary VistaGen Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about VistaGen Therapeutics

Checking the ongoing alerts about VistaGen Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for VistaGen Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
VistaGen Therapeutics had very high historical volatility over the last 90 days
VistaGen Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (59.25 M) with loss before overhead, payroll, taxes, and interest of (227.3 K).
VistaGen Therapeutics currently holds about 51.99 M in cash with (49.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Roughly 63.0% of the company outstanding shares are owned by institutional investors
Latest headline from businesswire.com: Vistagen to Present at the 2024 Anxiety and Depression Association Conference
When determining whether VistaGen Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of VistaGen Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vistagen Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vistagen Therapeutics Stock:
Check out VistaGen Therapeutics Backtesting, VistaGen Therapeutics Valuation, VistaGen Therapeutics Correlation, VistaGen Therapeutics Hype Analysis, VistaGen Therapeutics Volatility, VistaGen Therapeutics History as well as VistaGen Therapeutics Performance.
To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.
Note that the VistaGen Therapeutics information on this page should be used as a complementary analysis to other VistaGen Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for VistaGen Stock analysis

When running VistaGen Therapeutics' price analysis, check to measure VistaGen Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VistaGen Therapeutics is operating at the current time. Most of VistaGen Therapeutics' value examination focuses on studying past and present price action to predict the probability of VistaGen Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VistaGen Therapeutics' price. Additionally, you may evaluate how the addition of VistaGen Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Stocks Directory
Find actively traded stocks across global markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is VistaGen Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.96)
Revenue Per Share
0.077
Quarterly Revenue Growth
1.291
Return On Assets
(0.26)
Return On Equity
(0.45)
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.